Business Context and Reporting Period
Nanobiotix S.A., a French foreign private issuer, furnished this Form 6-K for June 2023. The filing reports that the company issued a press release on June 8, 2023, filed as Exhibit 99.1.
Financial and Operating Metrics
The filing text provided does not include financial statements, revenue, profit or loss, cash flow, margins, debt, liquidity, or other operating metrics.
Material Changes Versus Prior Period
The filing text does not provide information on material changes versus a prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
The referenced June 8, 2023 press release is incorporated by reference but is not included in the provided filing text. Accordingly, the filing text does not provide clear information regarding guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts to Verify
- Obtain and review Exhibit 99.1, the June 8, 2023 press release.
- Verify whether the press release contains financial, clinical, regulatory, financing, or business updates.
- Review Nanobiotix’s related Form 20-F and subsequent filings for financial metrics and liquidity information.
- Note that Bart Van Rhijn, Chief Financial Officer, signed the filing on June 8, 2023.